Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06251375 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Early Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients

Study acronym: SPICEIV
StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Minor Study sites: 0 to 1v9
  2. Minor Eligibility criteria expanded, about 7 wordsv8
  3. Notable Start date: Jun 30, 2025 to Sep 7, 2025v7
  4. Notable Start date: Jan 31, 2025 to Jun 30, 2025v6
  5. Notable Primary completion date: Dec 31, 2025 to Dec 31, 2027
    • Start date: Sep 2024 to Jan 31, 2025
    • Study completion date: Dec 31, 2025 to Jan 31, 2028
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Notable Start date: Jul 2024 to Sep 2024v4
  2. Notable Start date: Feb 2024 to Jul 2024v3
  3. Minor Re-verified, no change to tracked fieldsv2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sedation remains a ubiquitous and crucial component of intensive care treatments in critically ill mechanically ventilated patients. Sedation relieves anxiety, reduces distress, and promotes tolerance of endotracheal intubation and associated life-sustaining interventions such as mechanical ventilation, cardiovascular assistance, and renal support. Thus, choosing the optimal sedative agent is vital to patient comfort, safety, and survival. Despite more than 20 years of intensive care sedation research, there is still no consensus on what constitutes best sedation practice. The Society of Critical Care Medicine, the premier critical care organisation in North America, published the 2018 Clinical Practice Guidelines on the management of Pain, Agitation/Sedation, Delirium, Immobility and Sleep (PADIS) disruption (chaired by our primary applicant W.A.) and issued weak recommendations to provide analgesia before sedation, to target light sedation whenever clinically feasible, and to use either dexmedetomidine or propofol over midazolam for the sedation of mechanically ventilated critically ill patients. Similarly, the American Thoracic Society produced a set of Clinical Practice Guidelines to promote liberation and weaning from mechanical ventilation in critically ill patients, with weak recommendations for the use of non-benzodiazepines as primary sedatives and to target light sedation when clinically possible. A weak recommendation was issued in an Intensive Care Medicine Rapid Practice Guideline published in 2022 to use dexmedetomidine over propofol for sedation of critically ill adults, if the desired outcome is a reduction in delirium. These guidelines, however, do not consider age-dependent pharmacokinetics and pharmacodynamics, illness severity, timing of sedative administration, operative vs medical reason for admission, or the changing dynamics of sedation practice at different phases of critical illness. The lack of high-level evidence to inform sedation practice in the critically ill has led to approaches that are mainly opinion-based and lack the support of evidence from large multicentre, international randomised clinical trials.
Trial Details
NCT Number NCT06251375
Lead Sponsor St. Joseph's Healthcare Hamilton
Conditions
(from sponsor)
Respiratory Insufficiency
Related terms Respiratory Insufficiency
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov